Rosetta Genomics this week announced that it has established a US sales team that will handle the commercialization of its suite of microRNA-based diagnostics.
The team will particularly focus on Rosetta's miRview Mets and miRview Mets 2 tests, which are designed to determine the source of cancers of unknown primary origin.
Rosetta did not specify the size of the team, but said it will expand it “over the coming quarters.”
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
